P33 Étude épidémiologique et clinique de la dysfonction erectile du diabétique noir africain en cote d’ivoire

Lokrou, A.; Koffi, Djary Michel; Soumahoro, Sory Ibrahim; Derbé, A; Abodo, J.; Azoh, A.J.C.; Laubhouet, M.D.; Sanogo, Moumine; Doumbia, A.; Kouassi, F.; Hué, A.

doi:10.1016/s1262-3636(10)70181-6

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The prevalence found in our study was similar to that reported by Costa et al [8] in France who found a rate of 60%. This is in contrast to Gueye et al [9] in Se- negal and Lokrou et al [10] in the Ivory Coast who found a prevalence of 16% and 36.64% respectively. These results indicate the difficulty of evaluating ED (due to the use of different ED assessment tools), but may also be due to the small sample size of our study.…”

Section: Discussioncontrasting

confidence: 82%

Erectile Dysfunction among Diabetic Men in Two Medical Centers in Burkina Faso: Epidemiological, Diagnosis and Therapeutic Aspects

Kambou¹,

Zaré²,

Paré³

et al. 2014

ASM

View full text Add to dashboard Cite

Objective: To study erectile dysfunction in diabetic patients seen in two clinics in the city of Bobo-Dioulasso, Burkina Faso. Materials and Methods: A prospective cross-sectional descriptive study was conducted at the Sourô Sanou Teaching Hospital (CHUSS) and the Saint Leopold clinic in Bobo-Dioulasso, from March 1 to September 1, 2012. A total of 107 patients data were collated and analysed, which was then grouped into two: the ED group, designating patients with erectile dysfunction and the NED group consisting of those patients without. The sample comprised of 61 patients with types 1 and 2 diabetesand were aged between 25-70 years. The IIEF-5 was used to evaluate erectile dysfunction. Results: The prevalence of erectile dysfunction was 57%. The average age of patients was 54.4 ± 8.3 years. All patients with ED had type 2 diabetes. The mean disease duration of diabetes was 7.2 ± 6 years. Erectile dysfunction was severe in 32.8% of cases, moderate in 31.1% of cases and mild in 36.1%. Its severity was significantly associated with glycated hemoglobin, triglycerides and BMI. Phosphodiesterase types 5 (PDE5) inhibitors were found to be effective in the treatment of erectile dysfunction with a satisfactory therapeutic response in 77.4% of users. Conclusion: Erectile dysfunction is a common complication in diabetic patients. Its occurrence and severity are influenced by several factors. The potential presence of this disorder should be assessed due to its negative impact on quality of life. Phosphodiesterase type 5 inhibitors are an effective treatment modality in diabetic patients.

show abstract

Section: Discussioncontrasting

confidence: 82%